Recent News

May

09

AlphaBreak is a Phase 2/3 registrational program for FPI-2265 in patients with metastatic castration-resistant prostate cancer HAMILTON, ON and BOSTON, May 9, 2024 /PRNewswire/ -- Fusion...

May

07

Presented interim data from TATCIST trial of FPI-2265 in mCRPC at the 2024 American Association for Cancer Research (AACR) Annual Meeting Signed definitive agreement to be acquired by AstraZeneca...

Apr

25

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjucates (RCs) as precision medicines, today announced that it has filed...

View All

Overview

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vivamus fermentum urna dictum sem sollicitudin fringilla. Donec porttitor tristique congue. Vestibulum congue cursus nunc, at convallis augue pulvinar sit amet. Maecenas interdum rhoncus ullamcorper. Aliquam maximus purus in sapien bibendum, ac pulvinar ipsum venenatis. Praesent maximus sapien rhoncus massa tincidunt pretium. Vivamus ornare sem vitae purus efficitur luctus. Maecenas feugiat a lorem sit amet dignissim. Vestibulum varius tincidunt lobortis. Nulla maximus, nisi vitae tempus gravida, urna metus placerat diam, luctus mollis justo augue vel enim. Mauris condimentum convallis diam, eget sodales enim egestas sollicitudin. Donec vitae maximus risus, et euismod risus. Aliquam erat volutpat. Phasellus ultricies ac turpis nec dignissim. In auctor augue massa, vulputate ullamcorper ipsum ultricies non.

Stock Information
NASDAQFUSN
NEVER MISS AN UPDATE